Over €25 million raised since company inception from private investors, public institutions, international foundations and public innovation programs
Funding momentum strengthened by the arrival of new investors: Normandie Participation, TCD Capital and FIDAT Ventures
Resources intended to finalize regulatory studies, secure industrial manufacturing, and support LYS241’s entry into clinic, as part of a biomarker-rich Phase 1a/1b program with indication-specific cohorts across several neurological diseases.
Lyon & Caen, France, June 22, 2026 – Lys Therapeutics, a French biotechnology company pioneering an innovative approach targeting the tPA-NMDAr axis to treat neurodegenerative and neurovascular diseases, today announced that it has raised more than €25 million since its founding in 2021. In five years, the company has achieved several key preclinical, regulatory, industrial and translational maturation milestones, creating the conditions required to advance LYS241 into the clinic.
This major milestone reflects the confidence of investors and institutional partners in the technology developed by Lys Therapeutics and in the therapeutic potential of its drug candidate LYS241. The funding secured combines equity investments, non-dilutive public funding and support from international foundations dedicated to biomedical research.
